RAS Mutation Status and Immune Microenvironment in 225 pMMR Colorectal Cancer Patients

A retrospective analysis of 225 patients with proficient mismatch repair (pMMR) colorectal cancer, conducted by Shigang Wu and last updated in May 2026. The dataset likely contains multiplex immunohistochemistry data on immune cell densities and protein expression, used to define prognostic and predictive biomarkers for chemotherapy benefit. It focuses on the interplay between K/N-RAS mutational status and the tumor immune microenvironment.

Use Cases

• Predicting overall survival in pMMR colorectal cancer based on RAS mutation status and immune cell infiltration.
• Identifying patient subgroups likely to benefit from chemotherapy using biomarkers like CD163+ macrophage density.
• Modeling the divergent immune landscape shaped by RAS status for prognostic stratification.
• Analyzing the interaction between β-catenin/CMTM6 expression and chemotherapy response.

Strengths

• Includes data from 225 patient records, providing a defined cohort size.
• Multiplex immunohistochemistry quantified multiple immune cell types (CD4+, CD8+, CD68+, CD163+) and protein expressions (β-catenin, CMTM6, PD-L1).
• Analysis includes formal interaction testing with reported hazard ratios (e.g., HR=0.20 for CD163-high subgroup).

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data is presented in a DOCX file (16.0 KB), which may require extraction and structuring for analysis.
• The retrospective, single-study nature may limit generalizability.

Provenance

Source

figshare, author Shigang Wu.

Collection Method

Retrospective analysis using multiplex immunohistochemistry on patient samples.

Freshness

Last updated 2026-05-07 04:45:32; freshness should be verified.